Shares of Uniqure NV (NASDAQ:QURE) have been given a consensus recommendation of “Buy” by the nine ratings firms that are currently covering the stock. Three research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 1-year price target among brokers that have covered the stock in the last year is $12.45.
QURE has been the subject of a number of research analyst reports. Leerink Swann reaffirmed an “outperform” rating on shares of Uniqure NV in a research report on Friday, December 2nd. Jefferies Group LLC lowered Uniqure NV from a “buy” rating to a “hold” rating and decreased their target price for the company from $28.00 to $8.00 in a research report on Monday, November 28th. Oppenheimer Holdings Inc. set a $17.00 target price on Uniqure NV and gave the company a “buy” rating in a research report on Sunday, December 25th. Zacks Investment Research raised Uniqure NV from a “hold” rating to a “buy” rating and set a $6.50 target price for the company in a research report on Tuesday, December 20th. Finally, WallachBeth Capital decreased their target price on Uniqure NV from $27.00 to $15.00 and set a “buy” rating for the company in a research report on Tuesday, December 6th.
Hedge funds have recently modified their holdings of the company. Perceptive Advisors LLC bought a new stake in shares of Uniqure NV during the fourth quarter worth approximately $7,089,000. FMR LLC raised its stake in shares of Uniqure NV by 4.1% in the fourth quarter. FMR LLC now owns 1,175,118 shares of the company’s stock worth $6,580,000 after buying an additional 46,200 shares in the last quarter. City Financial Investment Co Ltd bought a new stake in shares of Uniqure NV during the fourth quarter worth approximately $1,492,000. Renaissance Technologies LLC raised its stake in shares of Uniqure NV by 6.8% in the fourth quarter. Renaissance Technologies LLC now owns 251,300 shares of the company’s stock worth $1,407,000 after buying an additional 15,950 shares in the last quarter. Finally, Baker BROS. Advisors LP bought a new stake in shares of Uniqure NV during the third quarter worth approximately $1,760,000. 29.84% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This piece of content was published by Mideast Time and is the property of of Mideast Time. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.mideasttime.com/brokerages-set-uniqure-nv-qure-price-target-at-13-21/1589522.html.
Uniqure NV (NASDAQ:QURE) remained flat at $5.81 during mid-day trading on Monday. 98,054 shares of the company traded hands. Uniqure NV has a 12-month low of $5.25 and a 12-month high of $15.00. The stock has a 50-day moving average price of $6.24 and a 200-day moving average price of $6.61. The firm’s market cap is $146.57 million.
About Uniqure NV
uniQure N.V. is engaged in the field of gene therapy. The Company is engaged in the discovery, development and commercialization of gene therapies. It has a technology platform that uses as the basis for collaborative product candidates across approximately three therapeutic focus areas, such as Liver/Metabolic Disease, Central Nervous System (CNS) Disease and Cardiovascular Disease.
Receive News & Ratings for Uniqure NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure NV and related companies with MarketBeat.com's FREE daily email newsletter.